FEZ2

Across TCGA pan-cancer cohorts, FEZ2 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated FEZ2 data layer compared with 3 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FEZ2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated FEZ2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SKCM show a favorable association.

LIHC, KIRC, and KIRP are the cancer types where FEZ2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.600	0.775	<.001	75	view →
KIRC	OS	Tertile	All	0.718	0.521	<.001	58	view →
KIRP	DFS	Tertile	III,IV	0.205	0.680	<.001	56	view →
STAD	DFS	Median	All	0.601	0.812	.001	49	view →
LGG	OS	Median	All	0.754	0.870	<.001	39	view →
SCLC	DFS	Tertile	II,III,IV	0.342	1.000	.006	38	view →
HNSC	DFS	Quartile	All	0.297	0.497	.010	30	view →
KICH	DFS	Quartile	II,III,IV	0.444	1.000	.001	27	view →
ACC	DFS	Median	All	0.579	0.869	.003	25	view →
SKCM	DFS	Tertile	All	0.670	0.528	.009	22	view →
CESC	DFS	Tertile	All	0.676	0.843	.002	20	view →
BLCA	DFS	Median	All	0.382	0.587	.008	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

FEZ2–LIHC (OS)

Open the LIHC breakdown →